Impacting Cancer

Nextech Invest, April 2018
Is this email not displaying correctly?
View it in your browser.

Dear Reader, 

The healthcare industry started 2018 with strong momentum. The first quarter included eleven IPOs, five of which were in oncology. Oncology company acquisitions by Celgene, Sanofi and Roche totaled USD 28 billion in market value. Biotech sentiment remained positive, with public companies bucking much of the negative trend in broader markets and technology, and private Biotech companies continuing to generate strong financing activity.

We are also pleased with the momentum we are seeing in our portfolio in 2018. In addition to significant clinical progress and equity appreciation in our existing portfolio, Fund V is off to a strong start, with four investments completed. The four companies; A2 Biotherapeutics, IDEAYA Biosciences, Revolution Medicines and Arvinas each possess cutting edge science, transformational platform technologies, world-class management teams and strong financial backing from some of the best investors in the industry. 

Most importantly, we are proud to announce the promotion of Rocco Sgobbo to Partner and welcome Suzanne Obenshain as Venture Partner to the Nextech family and our vision to building the leading oncology investment firm.

We look forward to seeing our Limited Partners at our Annual Investor Meeting in Boston on May 30th, where Novartis has kindly offered to host us on the campus of the Novartis Institute for BioMedical Research in Cambridge.

With kind regards, 
Your Nextech Team

Nextech News

The Nextech Team warmly welcomes Suzanne Obenshain as Venture Partner and heartily congratulates Rocco Sgobbo on his promotion to Partner and Chief Business Officer.  We look forward to continuing to shape the future of the Nextech team and to enabling new treatments for cancer patients together.

Portfolio News


We would like to welcome four leading companies to our portfolio marking the start of Fund V. We are excited about the transformational technologies of each of these companies combined with the world-class management teams and strong financing syndicates.

More information on each deal is provided below.


IDEAYA raises USD 94m Series B co-led by Nextech

Nextech completed the investment in IDEAYA Biosciences as co-lead investor of a USD 94m Series B financing.

Yujiro Hata, CEO of IDEAYA, shares his vision for the company and his perspectives of oncology in a Nextech exclusive interview.

Read the interview.

Other investors in the Series B include BVF, Perceptive, Celgene, Novartis, Roche Venture Fund and existing investors 5AM Ventures, Canaan Partners and Wuxi Ventures. Proceeds will be used to advance several assets into clinical development towards proof-of-concept. Lead programs are focused on synthetic lethality and immuno-oncology targets in cancer. IDEAYA is located in South San Francisco, CA, USA.

Read the press release and BioWorld article.


Arvinas raises USD 55m Series C led by Nextech


Nextech completed the investment in Arvinas as lead investor of a USD 55m Series C financing. Other investors include Deerfield and Hillhouse as well as existing investors Caanan Partners, 5AM Ventures, Orbimed, RA Capital, New Leaf Venture Partners and Elm Street Ventures. Arvinas was founded by Craig M. Crews, PhD, the pioneer in targeted protein degradation, and is based in New Haven, CT, USA. The company is led by John G. Houston, PhD. Arvinas has entered into partnerships with three pharma industry leaders: Genentech, Merck and Pfizer. Funds will be used to advance the two lead programs which target the androgen and estrogen receptors for prostate and breast cancers into the clinic and broaden the pre-clinical pipeline.

Read the press release and Endpoints article.


Revolution Medicines raises USD 56m Series B led by Nextech


Nextech completed the investment in Revolution Medicines as lead investor of a USD 56m Series B financing. Other investors include Third Rock Ventures, The Column Group, Casdin Capital, Schroder Adveq, and additional undisclosed institutional investors. Revolution Medicines is located in Redwood City, CA, USA and is led by Mark A. Goldsmith, MD, PhD. The financing will be used to advance the lead SHP2 inhibitor into Phase I clinical development and to further advance the preclinical stage assets towards clinical development.

Read the press release and Endpoints article.


Charles Saywers, MD, member of the Nextech Scientific Board, provides insight about the opportunity in target therapies in a Nextech exclusive video interview.

Watch the video.


Autolus announced its draft registration for potential IPO in the United States.

Read the press release.

Autolus announced an oral presentation at the AACR Annual Meeting of a Phase I study of GD2 CAR-T cell therapy in patients with neuroblastoma.

Read the press release.

Blueprint Medicines [BPMC] presented proof-of-concept data from ongoing Phase I clinical trial of BLU-667 in a clinical trials plenary session at AACR Annual Meeting in Chicago.

Read the press release.

Kura Oncology [KURA] was added to the NASDAQ Biotechnology Index (NBI) and provided update on Phase II trial of tipifarnib in HRAS mutant Head and Neck Cancer.

Read the press releases.

Jounce Therapeutics [JNCE] was added to the NASDAQ Biotechnology Index and announced presentation of preliminary efficacy data for the Phase I/II ICONIC trial at the ASCO conference in Chicago.

Read the press releases

Neon Therapeutics completed USD a 106m crossover Series B financing.

Read the press release.

Neon Therapeutics expands Board of Directors with leading experts in cancer drug discovery and corporate finance.

Read the press release.

Tracon Pharmaceuticals [TCON] announced a USD 38.7m private placement.

Read the press release.

Nextech Invest Ltd.
Bahnhofstrasse 18
8001 Zurich, Switzerland